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Aims:  A network meta-analysis (NMA) of all recommended drug groups for the treatment of 
heart failure with reduced ejection fraction (HFrEF), including their combinations, was 
performed to assess the relative efficacy and incremental benefit. 
Methods and Results: A search was made in biomedical databases for randomised controlled 
trials published between 1987 and 2017 on angiotensin-converting enzyme inhibitors (ACEI), 
beta-blockers (BB), angiotensin-II receptor blockers (ARB), mineralocorticoid receptor 
antagonists (MRAs), ivabradine (IVA) or angiotensin receptor/neprilysin inhibitors (ARNI). 
A total of 58 relevant trials were identified. The relative efficacy of each treatment group (or 
combination) in terms of all-cause mortality, cardiovascular (CV) mortality, all-cause 
hospitalizations and hospitalizations for HF, per patient-year of follow-up, were combined in 
a random-effects Bayesian NMA. The pairwise comparison between each regimen and for 
each outcome was estimated.  
The NMA was dominated by 15 large-scale trials with between 1984 and 18898 patient-years 
of follow-up. Combinations of drug groups showed incremental benefits on outcomes over 
single groups. The most effective combinations were ARNI+BB+MRA and 
ACEI+BB+MRA+IVA, showing reductions in all-cause mortality (versus placebo) of 62% 
and 59%, respectively; hazard ratios were 0.38 (Credible Interval [CrI]: 0.16–0.71) and 0.41 
(CrI: 0.19–0.82); and in all-cause hospitalizations with reductions of 42% for both. These two 
combinations were also the most effective for the other outcomes studied.  
Conclusion:  Our analysis shows that the incremental use of combinations of disease-
modifying therapies has resulted in the progressive improvement in mortality and 
hospitalization outcomes in HFrEF. Our findings support the current guideline 
recommendations. 
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Introduction 
Despite recent therapeutic gains, heart failure (HF) remains a major cause of mortality and of 
hospitalizations worldwide. Its prevalence has been put at approximately 1–2% of the adult 
population in developed countries; more recent forecasts alarmingly predict more than 
doubling of this prevalence (1-3). The therapeutic management of chronic HF, particularly for 
patients with reduced ejection fraction (HFrEF), is built mainly around drug combinations 
including, angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers 
(ARBs), beta blockers (BBs), mineralocorticoid receptor antagonists (MRAs) and diuretics. 
Recently, the international guidelines in Europe (1) and in USA (4) for the treatment of 
HFrEF have been updated to include the use of sacubitril/valsartan (ARNI; for angiotensin 
receptor/neprilysin inhibitor) and ivabradine (IVA; a sinus node If channel inhibitor that 
reduces heart rate). 
Over the last three decades, the implementation of guideline-recommended drug treatments 
for HFrEF has resulted in a decline of HF mortality (5), but early post-discharge mortality and 
hospital readmission rates have remained stable or may even be worsening due to the 
complexity of multiple comorbidities in ageing HF patients and to the lack of implementation 
of recommended medications or proper titration of these drugs (6;7).  
Network meta-analysis and multiple treatment comparisons of randomized controlled trials 
(RCTs) facilitate the indirect comparisons of multiple interventions that have not been studied 
in head-to-head studies. These methods are attractive for clinical researchers because they 
seem to respond to their main concern: determining the best available intervention. 
A recently published meta-analysis of drug treatment for HFrEF (8) has emphasized the 
benefits of certain drug combinations over the last 30 years. However by focusing only on all-
cause mortality as an endpoint and not including all the recommended drug groups, the review 
does not fully reflect the burden of the disease and the options available. Thus, in order to 
provide a more comprehensive picture of the impact of therapy and in particular on the burden 
of hospitalizations, we reviewed all available evidence regarding the pharmacological 
treatment of chronic HFrEF including all guideline-recommended drug groups on the 
endpoints of all-cause mortality, cardio-vascular mortality, hospitalization for heart failure 
and all-cause hospitalization. 
Methods 
Identification and Selection of Studies  
The databases PubMed, EMBASE, and Cochrane CENTRAL were searched using a strategy 
adapted from the above mentioned review (8), for the period January 2015 until May 2017.  A 
search was made for the main drug groups for the treatment of HF (ACEIs, BBs, ARBs, 
MRAs) and the newer groups, including If channel blockers (namely, ivabradine; IVA) and 
angiotensin receptor/neprilysin inhibitors (ARNI; namely, valsartan/sacubitril or LCZ696). 
Studies were considered if they were RCTs and comparisons of drug efficacy within the same 
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drug group were excluded. The retrieved studies were added to the list of studies provided in 
reference 8; there was only one addition, the SHIFT trial of ivabradine (9). 
The target studies were limited to those in adult outpatients (aged ≥18 years to 70 years) with 
chronic HFrEF (LVEF < 45%) of ischemic or idiopathic aetiology. The review focused on 
studies conducted principally in North America or Europe. Excluded, were studies where the 
entire population comprised patients with a concomitant diagnosis that was likely to have a 
major effect on endpoint attainment (e.g. acute heart failure, chronic obstructive pulmonary 
disease, diabetes mellitus, renal failure, coronary heart disease). The PRISMA diagram 
showing the search and selection of references is provided in the supplementary data, along 
with the list of references excluded on full text. 
Information from the reports of the included studies was entered into a database (double entry 
with reconciliation). For each endpoint, the total number of events was extracted for each arm. 
The exposure time was the mean or median follow-up time if reported, or else the planned 
study duration. To account for concomitant therapy in the trials, treatments were categorized 
by drug group combination using a patient threshold of 50%; thus if >50% of the trial patients 
received concomitant drugs of interest (e.g. ACEI and BB), the treatment was described as a 
combination therapy (the study drug group + the concomitant drug group). 
Network Meta-Analysis  
Network meta-analysis (NMA) is a statistical method that combines direct (i.e. head-to-head) 
and indirect evidence (i.e. via one or more common comparator(s)) in a mixed treatment 
comparison (10). It therefore facilitates indirect comparisons of interventions that have not 
been studied in head-to-head studies. In such analyses, the treatments form a connected 
network, i.e. there is path from each treatment to every other treatment in the network. For 
consistency, we used same methodology as in the previous NMA in heart failure (8), with a 
modelling framework proposed by Dias et al (11). This comprises a random-effects model 
within a Bayesian framework using R software and Winbugs 1.4. The model input was arm-
level data, using the numbers of patients with at least one event at the end of the trial, the total 
number of patients randomized, and the mean or median follow-up duration (of the overall 
trial). The log mean follow-up time was used to transform the probability of an event into a 
constant rate for each trial arm by assuming an underlying Poisson process. A complementary 
clog–log (cloglog) link was used to model the event rates. Non-informative priors were used. 
Outputs from the model are presented as hazard ratios (HRs) for each treatment versus 
placebo with 95% credible intervals (CrI) for the Bayesian probability that the treatment is 
better than placebo. Results were also computed for all pairwise comparisons. 
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Results   
Study Selection   
A total of 58 RCTs were included, constituting the diagram presented in Figure 1. This 
network forms a quasi-chronological progression of therapeutic advance starting from the top. 
Although many later studies compared their investigational treatment with standard of care, 
the analysis here is designed to calculate the treatment effect as compared with placebo (i.e. 
the absence of any of the studied drug groups). 
The included trials were mostly multicentre, double-blind, placebo-controlled trials, although 
they varied considerably in terms of size and follow-up duration. Nine of the studies included 
less than 100 patients, whereas eleven included more than 2000. Follow-up durations ranged 
from 8 weeks, with 16 studies lasting 3 months or less, to 4 years, with 18 studies that were 
over 1 year. The severity of HF in the included patients ranged from mild in SOLVD-prevent 
(with 66% NYHA class I and 34% class II) to severe in CONSENSUS (with 100% class IV). 
The full list of studies is presented in the supplementary data section. The network was 
dominated by a few large-scale studies and these are listed in Table 1. These tended to be the 
more recent ones, reflecting the need to have larger studies to demonstrate the incremental 
benefit of added treatments. 
When the study data are viewed in terms of patient-years of follow-up for the investigational 
arms of the included treatments (Figure 2A), the weight of evidence provided by the larger 
study programs is clear. It might also be noted that the heart failure indication for each of 
ARNI and ivabradine was informed by a single RCT. When the patient follow-up by drug 
group in this indication is considered (Figure 2B), it can be seen that the evidence is 
dominated by the studies of ARBs, beta-blockers, ARNI and ivabradine. 
As might be expected given the variety in the included studies in terms of inclusion criteria, 
design and endpoint adjudication (all-cause mortality excepted), there is a significant amount 
of heterogeneity in the network for each endpoint, resulting in some uncertainty in 
comparative estimates. For example the heterogeneity parameter for all-cause mortality was 
between-study variability=0.17 (95% CrI 0.05 – 0.35); for all-cause hospitalizations this 
measure was slightly lower, but for other endpoints it was higher (supplementary data). The 
main results of the NMA for each drug group, or combination of groups, versus placebo for 
each endpoint, are summarized in Table 2. The results for each endpoint are also illustrated in 
forest plots (Figures 3 – 6), which show the hazard ratio for each treatment with its 95% 
credible interval. The full results of the NMA are presented in the supplementary data section 
with a separate matrix for each endpoint. It should be noted that the comparisons are 
presented versus placebo and do not necessarily emanate from an RCT; the network meta-
analysis provides this placebo-comparison in an indirect manner. 
All treatment groups or combinations were associated with some reduction in risk. The most 
efficacious treatment combinations versus placebo are found at the top of the figures with the 
point estimates relatively far (to the left) from the null-effect indicator of 1.0.  
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In the forest plot for all-cause mortality (Figure 3) it can be seen that all of the combination 
therapies as well as BB monotherapy have 95% CrI’s and the point estimate shows superiority 
of the combination over placebo. The best combinations are ARNI+BB+MRA and 
ACEI+BB+MRA+IVA with a relative risk reduction of 62% and 59% respectively. Of the 
triple therapies, the combination ACEI+BB+MRA results in a somewhat better result than 
ACEI+ARB+BB.  
In the forest plot for CV mortality (Figure 4), the trend in HR estimates is quite similar to 
those already described for all-cause mortality, with the exception of BB monotherapy, which 
did not appear to perform so well on this endpoint. The credible intervals are wider for this 
comparison than all-cause mortality because fewer studies reported this endpoint (n = 41).  
The data for all-cause hospitalization are presented in Figure 5. The best performing 
combinations appear once again to be ARNI+BB+MRA and ACEI+BB+MRA+IVA (relative 
risk reduction of 42% for both) although other combinations, such as ACEI+ BB+MRA (35% 
reduction), are close behind. A total of 21 studies reported this endpoint.  
In the forest plot for hospitalizations due to worsening HF (Figure 6), all treatment groups or 
combinations were associated with some reduction in risk. The best performing combinations 
were ACEI+BB+MRA+IVA, ACEI+ARB and ARNI+BB+MRA. However the credible 
intervals are wider here, indicating a lower precision in the estimates. A total of 28 studies 
reported this endpoint. 
The pairwise comparisons of all treatments (and treatment combinations), for each endpoint, 
are provided in Appendix Table 1. The matrices indicate the estimated treatment effect (and 
CrI) for each treatment pair along with the Bayesian probability that one is better than the 
other. The hierarchy of treatment combinations versus single treatment group comparators 
was very similar to the comparisons versus placebo. For each endpoint, there was little 
difference in efficacy between the most effective combinations: for all-cause death, hazard 
ratios for ACEI+BB+MRA+IVA versus ARNI+BB+MRA and ACEI+BB+MRA were 1.08 
(CrI: 0.61;0.91) and 0.91 (0.6;1.36) respectively; for hospitalization due to worsening HF, the 
hazard ratios for ACEI+BB+MRA+IVA versus ARNI+BB+MRA and ACEI+BB+MRA were 
0.93 (CrI: 0.24;3.61) and 0.75 (CrI: 0.29;1.96) respectively 
 
Discussion   
Our results, based on the analysis of relevant clinical trials conducted between 1987 and 2017, 
show that the combination of disease modifying medications, i.e. ACEI, ARB, BB, MRA 
ivabradine and ARNI, resulted in the progressive improvement over the last 30 years in 
mortality and hospitalization outcomes in HFrEF. This improvement may be visualized, for 
each of the endpoints studied, by the leftward progression of the point estimates, with 
intensifying combinations of drug groups. Overall, our network analysis validates the 
recommendations made by international guidelines. 
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Among the different possible combinations, those including the most recently developed 
drugs, ivabradine and sacubitril/valsartan are among the most efficacious: ARNI+BB+MRA 
and ACEI+BB+MRA+IVA tended to be the combinations associated with the lowest point 
estimates of HR versus placebo for the mortality endpoints and for hospitalizations. There 
was a relative risk reduction of 62% and 59%, respectively on all-cause death, 64% and 59% 
on CV deaths, 42% and 42% on all-cause hospitalizations, and 73% and 75% on 
hospitalizations for worsening HF. However, none of these estimates can be taken as strong 
evidence of superiority over other combinations and it is clear that the options need to be 
carefully weighed given the characteristics of the individual patient.  Numerous factors 
including rhythm (sinus or atrial fibrillation), heart rate at baseline, low systolic blood 
pressure, severe kidney disease can influence the  choice of ARNI or ivabradine as third line 
therapy in HFrEF based on the respective indication and contra indication of each drug. 
However this combination of the two drugs is recommended by ESC guidelines if the 
patient’s profile fits. 
While individual RCTs are not always easy to compare given the differences in the entry 
criteria, recent analyses have concluded that the proportion of deaths adjudicated as 
cardiovascular has decreased over the last 30 years (12;13). The noteworthy effect of the 
combinations of disease modifying therapies observed in the clinical trials included in this 
analysis may however not fully translate to the real-life situations due to the inherent selection 
bias of patients enrolled in randomized trials whereas observational studies show that HF 
patients usually have a constellation of comorbidities and are generally older than those 
studied in clinical trials (14). However, it has been shown that adherence to guideline 
recommended therapies is associated with improved outcomes in observational studies (14). 
The results of the meta-analysis should therefore encourage physicians to apply the most 
efficacious combinations of HF medications. 
The recent guidelines of the European Society of Cardiology (2016) emphasize the need to 
reduce the burden of hospitalizations and rehospitalizations as one of the major goals of the 
management of HFrEF (1) and the importance of this goal has been recently highlighted in a 
position paper regarding the conduct of future heart failure trials (15). Therefore, our analysis 
included not only mortality data but also all cause hospitalizations and HF hospitalizations 
together with the totality of available drugs tested in randomized controlled trials. It therefore 
extends the results of a previous meta-analysis to hospitalizations and finds a similar stepwise 
improvement of all cause death and of HF hospitalizations by modern combinations.  
The review has a number of limitations. The start date for the literature search (January 1987) 
was arbitrary and chosen to capture a 30-year time span. This choice resulted in the omission 
of a few potentially relevant studies, notably some earlier captopril trails. Some important 
trials in high-risk CV patients were excluded because of the decision to focus on patients with 
established HF. Thus the trials, SAVE (16), AIRE (17) and HOPE (18), which were important 
in establishing ACE inhibitors as standard of care in patients at high CV risk or post-
myocardial infarction were not included in the analysis. A large number of small short-term 
studies (often designed to investigate drug effects on biomarkers or exercise tolerance) were 
included in the review, which may have introduced spurious information since the mean 
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mortality rates were relatively higher in these than in the longer term trials (e.g. 0.16 deaths 
per patient-year in 3-month trials versus 0.07 deaths per patient-year in trials lasting >30 
months). The review included treatments which do not have an indication in HF, namely: 
benazepril, imidapril, spirapril, telmisartan, celiprolol, bucindolol, atenolol, and canrenone, 
since the focus was on the drug groups only. Prescription of drugs with certain groups and not 
dosage used was considered for this analysis.  This approach may have diluted the treatment 
effect of drugs with the indication. Our meta-analysis was based on the recommended add-on 
or substitution strategy and did not address other potential strategies such as ACEI + MRA + 
IVA, ARNI + IVA or ARNI + BB + digoxin, which might only be validated by properly 
designed clinical trials. It should also be noted that the patients enrolled in RCTs may not 
represent the real life situation by being relatively younger and having fewer comorbidities. 
Finally since 30 years separates the oldest and the most recent trials included in our analysis, 
it is possible that the profile and the environment of patients enrolled in these trials has 
changed significantly over time. The statistical analysis of the retrieved data indicates a fairly 
large amount of uncertainty for several of the comparisons, reflecting the limitations already 
mentioned.  
In conclusion, our analysis of relevant clinical trials published between 1987 and 2017, shows 
that the incremental use of combinations of disease modifying therapies, i.e. ACEIs, ARBs, 
BBs, MRAs, ivabradine and ARNI, has resulted in the progressive improvement over the last 
30 years in mortality and hospitalization outcomes in HFrEF. Our findings, illustrating the 
success of disease-modifying combinations, support the guideline recommendations. 
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11. Figure Legends (296 words) 
Figure 1: The evidence network of studies reporting all-cause mortality. The thickness of the connecting 
lines corresponds to the number of patient-years of evidence (5 indicative thicknesses) for each drug 
group/combination comparison. The contributing studies are indicated in the adjoining panels with the 
number of randomized patients that contributed to the analysis in parenthesis and the cumulative total of 
patient-years of evidence. The supplementary data includes networks for the other endpoints investigated 
in this review.  
Figure 2A: Patient-years of evidence for the investigational arms of the included treatments (thus more 
than one study might contribute to evidence total). B: Patient-years of evidence for the investigational 
arms of the included treatment groups. Note: The evidence from the SOLVD Prevent study is not 
represented in these figures. 
Figure 3: Forest plot of hazard ratios and their 95% CrIs for all-cause mortality for treatment versus 
placebo (random-effects model without adjustment). Hazard ratio < 1 favours treatment. The size of the 
square is proportional to the number of patients in the comparison. 
Figure 4: Forest plot of hazard ratios for CV mortality (random-effects model without adjustment). The 
point estimates with a value less than one signify a relative superiority of the active treatment and the 
whiskers mark the limits of the 95% credible interval.  
Figure 5: Forest plot of hazard ratios for all-cause hospitalization (random-effects model without 
adjustment). The point estimates with a value less than one signify a relative superiority of the active 
treatment and whiskers mark the limits of the 95% credible interval.  
Figure 6: Forest plot of hazard ratios for hospitalization due to worsening HF (random-effects model 
without adjustment). The point estimates with a value less than one signify a relative superiority of the 
active treatment and the whiskers mark the limits of the 95% credible interval.  
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HEAVEN (n=141) 
Val HeFT (n=5010) 
Hamroff 1999 (n=33) 
RESOLVD (n=175)* 
CHARM-Added (n=2548) 
EMPHASIS-HF (n=2737) 
AREA IN-CHF (n=467)  
Vizzardi 2014 (n=130) 
Cicoira 2002 (n=106) 
SHIFT (n=6558) 
PARADIGM-HF (n=8399) 
* Highest dose considered 
# Total for considered comparison 
23223 patient-years 
181 patient-years 
5527 patient-
years 
3326 patient-years 
287 patient-years 
5695 patient-years 
33 patient-years 
9619 patient-years 
81 patient-years 
8706 patient-years 
18552 patient-years 5839 patient-years 
12515 patient-years 
18898 patient-years 
1077 patient-years 
All-cause Deaths 
Placebo 
ARNI; 9477 
Candesartan; 7305 
Ivabradine; 6236 
Valsartan; 4829 
Enalapril; 4519 
Losartan; 2749 
Bucindalol; 2708 
Metoprolol; 2087 
Bisoprolol; 2599 
Eplerenone; 2387 
Spironolactone; 1936 
Carvedilol; 2034 Other; 1066 
ARB; 14900 
BB; 9969 
ARNI; 9477 
Ivabradine; 6236 
ACEI; 4954 
MRA; 4554 




13. Tables 
 
 
Table 1: Contributing studies that have at least 1000 patient-years of evidence, ordered 
by year of publication  
Name of study 
Year 
Published Drug entity 
Patients 
(randomized) 
Median 
duration 
Patient-years 
of evidence 
SOLVD Treat  1991 Enalapril 2569 3.5 8863.1 
SOLVD Prevent  1992 Enalapril 4228 3.1 13177.3 
CIBIS  1994 Bisoprolol 641 1,9 1217.9 
CIBIS-II  1999 Bisoprolol 2647 1.3 3441.1 
MERIT-HF  1999 Metoprolol 3991 1,0 3991.0 
RALES  1999 Spironolactone 1663 2.0 3326.0 
ELITE II 2000 Losartan 3152 1.5 4789.5 
BEST  2001 Bucindolol 2708 2.0 5416.0 
Val-HeFT  2001 Valsartan 5010 1.9 9602.5 
CHARM Alternative 2003 Candesartan 2028 2.8 5695.3 
CHARM Added 2003 Candesartan 2548 3.4 8705.7 
COPERNICUS  2003 Carvedilol 2289 0.9 1983.8 
SHIFT  2010 Ivabradine 6558 1.9 12514.9 
EMPHASIS-HF  2011 Eplerenone 2737 1.8 4789.8 
PARADIGM-HF  2014 Valsartan/sacubitril 8399 2.3 18897.8 
 
  
Table 2: Summary results of treatment effect versus placebo for each drug group or combination of 
groups and for each endpoint.  
 
 
Results of the NMA: Hazard ratios and their 95% CrIs versus placebo; n.a. no available result. 
 
Estimate (95% CrI) 
All-cause 
mortality 
CV mortality 
All-cause 
Hospitalization 
Hospitalization 
for HF 
ARNI+BB+MRA 0.38 (0.20;0.65) 0.36 (0.16;0.71) 0.58 (0.36;0.92) 0.27 (0.07;1.07) 
ACEI+BB+MRA+IVA 0.41 (0.21;0.70) 0.41 (0.19;0.82) 0.58 (0.36;0.92) 0.25 (0.07;0.99) 
ACEI+BB+MRA 0.44 (0.27;0.67) 0.45 (0.25;0.75) 0.65 (0.45;0.93) 0.34 (0.13;0.91) 
ARB+BB 0.48 (0.24;0.86) 0.50 (0.19;1.12) 0.79 (0.47;1.21) 0.31 (0.07;1.29) 
ACEI+ARB+BB 0.52 (0.32;0.80) 0.47 (0.24;0.82) 0.74 (0.46;1.04) 0.42 (0.16;1.23) 
ACEI+BB 0.58 (0.42;0.73) 0.56 (0.37;0.75) 0.75 (0.54;0.92) 0.34 (0.17;0.56) 
ACEI+MRA 0.58 (0.36;0.90) 0.56 (0.31;0.95) 0.69 (0.45;0.96) 0.36 (0.12;0.96) 
BB 0.58 (0.34;0.95) 0.62 (0.27;1.32) 0.86 (0.59;1.18) 0.45 (0.13;1.39) 
ACEI+ARB 0.83 (0.52;1.23) 0.80 (0.43;1.33) n.a. 0.26 (0.08;0.57) 
ACEI 0.84 (0.67;1.01) 0.81 (0.60;1.04) 0.89 (0.71;1.05) 0.52 (0.32;0.76) 
ARB 0.89 (0.61;1.27) 0.85 (0.51;1.28) 0.81 (0.56;1.01) 0.53 (0.26;1.03) 
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Prisma flow diagram 
1447 records identified for 
2015 - 2017:  
263 Medline; 527 Embase;  
657 Cochrane 
1441 records excluded on 
title/abstract 
Mostly on patient population  
or study design 
6 records assessed for 
eligibility on full-text 
1 record retained for 
further detailing the 
Paradigm study 
Burnett list:  
57 RCTs 
Ivabradine HF 
(pre 2015):  
1 RCT 
58 RCTs included in 
analysis 
1 
CV Deaths 
BB ACEI 
BB 
 + 
ARB  
ARB 
ACEI 
+ 
ARB 
ACEI 
+ BB 
ACEI 
+ 
MRA 
ACEI 
+BB 
+ 
ARB 
ACEI 
+ BB 
+ 
MRA 
BB + 
MRA 
+ 
ARNI 
ACEI + 
BB + 
MRA + 
IVA 
Contributing studies 
ordered by decreasing size 
CARMEN (n=381)# 
RALES (n=1663)  
CARMEN (n=382)# 
CHARM Alt (n=2028) 
CHARM-Added (n=2548) 
EMPHASIS-HF (n=2737) 
AREA IN-CHF (n=467) 
Vizzardi 2014 (n=130)  
SHIFT (n=6558) 
PARADIGM-HF (n=8399) 
22553 patient-years 
118 patient-years 
5510 patient-years 
3326 patient-years 
287 patient-years 
5695 patient-years 
8706 patient-years 
15214 patient-years 5733 patient-years 
12515 patient-years 
18898 patient-years 
572 patient-years 
* Highest dose considered 
# Total for considered comparison 
SOLVD-prevent  (n=4228) 
SOLVD-treat  (n=2569) 
FEST  (n=308) 
CONSENSUS  (n=253) 
Brown 1995 (n=241) 
Shettigar 1999 (n=206) 
Colfer HT, 1992 (n=172)  
Lewis 1989 (n=130)  
van Veldhuisen 1998 (n=122) * 
STRETCH (n=424) * 
Mitrovic 2003 (n=88)  
ELITE  II (n=3152)  
ELITE I (n=722)  
REPLACE (n=154)*  
Lang 1997 (n=78)   
Val HeFT (n=5010) 
Hamroff 1999 (n=33) 
9619 patient-years 
HEAVEN (n=141) 
33 patient-years 
MERIT-HF (n=3991)  
BEST (n=2708) 
CIBIS-II (n=2647) 
Packer (n=1094) 
CIBIS (n=641) 
CARMEN (n=381) 
MOCHA (n=173) * 
CELICARD 2000 (n=132) 
Sturm 2000 (n=100) 
MERIT-HF-pilot (n=61)  
De Milliano 2002 (n=54) 
MIC (n=52)  
SYMPOXYDEX (n=50)  
Dubach 2002 (n=28) 
Placebo 
1 
All Hospitalisations 
BB ACEI 
BB 
 + 
ARB  
ARB 
ACEI 
+ 
ARB 
ACEI 
+ BB 
ACEI 
+ 
MRA 
ACEI 
+BB 
+ 
ARB 
ACEI 
+ BB 
+ 
MRA 
BB + 
MRA 
+ 
ARNI 
ACEI + 
BB + 
MRA + 
IVA 
SOLVD-prevent  (n=4228) 
SOLVD-treat  (n=2569) 
CASSIS (n=147) * 
 
Contributing studies 
ordered by decreasing size 
BEST (n=2708) 
CIBIS-II (n=2647) 
MOCHA (n=173) * 
ENECA (n=260) 
 
SPICE (n=270) 
Mitrovic 2003 (n=88)   
ELITE  II (n=3152)  
ELITE I (n=722)  
CIBIS-III (n=1010)  
CARMEN (n=381)# 
RALES (n=1663)  
CARMEN (n=382)# 
CHARM Alt (n=2028) 
CHARM-Added (n=2548) 
EMPHASIS-HF (n=2737) 
AREA IN-CHF (n=467)  
SHIFT (n=6558) PARADIGM-HF (n=8399) 
22074 patient-years 
83 patient-years 
5456 patient-years 
3326 patient-years 
287 patient-years 
5695 patient-years 
8706 patient-years 
9192 patient-years 5257 patient-years 
12515 patient-years 18898 patient-years 
1077 patient-years 
* Highest dose considered 
# Total for considered comparison 
Placebo 
1 
HF Hospitalisations 
BB ACEI 
BB 
 + 
ARB  
ARB 
ACEI 
+ 
ARB 
ACEI 
+ BB 
ACEI 
+ 
MRA 
ACEI 
+BB 
+ 
ARB 
ACEI 
+ BB 
+ 
MRA 
BB + 
MRA 
+ 
ARNI 
ACEI + 
BB + 
MRA + 
IVA 
SOLVD-prevent  (n=4228) 
SOLVD-treat  (n=2569) 
FEST  (n=308) 
CONSENSUS  (n=253) 
Brown 1995 (n=241) 
Shettigar 1999 (n=206) 
Goldstein 1988 (n=204) 
Beller 1995 (n=193) 
 
Contributing studies 
ordered by decreasing size 
BEST (n=2708) 
CIBIS-II (n=2647) 
CARMEN (n=381)# 
Colucci 1996 (n=366) 
MOCHA (n=173) * 
Sturm 2000 (n=100) 
MERIT-HF-pilot (n=61)  
 
SPICE (n=270)  
ELITE  II (n=3152)  
ELITE I (n=722)  
CARMEN (n=381)# 
RALES (n=1663)  
CARMEN (n=382)# 
CHARM Alt (n=2028) 
Val HeFT (n=5010) 
RESOLVD (n=175)* 
CHARM-Added (n=2548) 
EMPHASIS-HF (n=2737) 
AREA IN-CHF (n=467)  
SHIFT (n=6558) PARADIGM-HF (n=8399) 
22602 patient-years 
62 patient-years 
5456 patient-years 
3326 patient-years 
287 patient-years 
5695 patient-years 
9603 patient-years 
81 patient-years 
8706 patient-years 
9388 patient-years 5257 patient-years 
12515 patient-years 18898 patient-years 
572 patient-years 
* Highest dose considered 
# Total for considered comparison 
Placebo 
